Skip to content
Spiritual Quotes – Lifestyle
Author:
Olema Oncology
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
May 26, 2026
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
May 19, 2026
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
May 12, 2026
←
Previous Page
1
2